20 October 2023
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS LIMITED
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 19 October 2023. Please see further detail as follows:
| 1. | To recommend the approval of the Financial Statements for the year ended 30 June 2023 | The Audited Financial Statements for the year ended 30 June 2023 have been approved. The full accounts are expected to be announced by 01 November 2023 |
| 2. | Date & Time of 47th Annual General Meeting ("AGM") of the Company for the year ended 30 June, 2023 | 28 December 2023 at 10.30 A.M. |
| 3. | Venue of AGM | Virtual Platform
|
| 4. | Proposed Dividend for the year ended 30 June 2023 | 35% Cash Dividend (i.e. Tk 3.50 per Share) |
| 5. | Record date | 13 November 2023 |
Comparative Financial Disclosures:
Beximco Pharmaceuticals Limited (Stand-alone)
| Particulars | Year ended 30 June 2023 | Year ended 30 June 2022 |
| Net Profit after Tax | Tk. 4,588,008,908 | Tk. 5,161,343,643 |
| Earnings Per Share (EPS) | Tk. 10.28 | Tk. 11.57 |
| Net Asset Value (NAV) | Tk. 43,341,239,142 | Tk. 40,315,738,301 |
| Net Asset Value per share (NAVPS) | Tk.97.15 | Tk. 90.37 |
| Net Operating Cash Flow Per Share (NOCFPS) | Tk. 12.96 | Tk. 11.27 |
Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)
| Particulars | Year ended 30 June 2023 | Year ended 30 June 2022 |
| Net Profit after Tax | Tk. 4,524,468,490 | Tk. 4,998,628,197 |
| Earnings Per Share (EPS) | Tk. 10.34 | Tk. 11.48 |
| Net Asset Value (NAV) | Tk. 43,680,703,738 | Tk. 40,600,497,817 |
| Net Asset Value per share (NAVPS) | Tk. 97.91 | Tk. 91.01 |
| Net Operating Cash Flow Per Share (NOCFPS) | Tk. 13.64 | Tk. 11.69 |
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma?s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.